ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PARP1 Inhibitor HRS-1167

Also written as “M9466”, “HRS-1167 tablets” and “HRS-1167”.

Its studies are mostly in Prostatic Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pagePARP1 Inhibitor HRS-1167: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 26, 20246 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine33 open or runningphase 2since Feb 26, 2024Jul 13, 2022Dec 31, 2026phase 1 · NCT05473624
Merck KGaA, Darmstadt, Germanyits history only31 open or runningphase 1since May 14, 2024May 14, 2024Feb 22, 2027phase 1 · NCT06421935

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05473624 · 153 planned · China
  2. Feb 26, 2024Phase 2 study in Ovarian NeoplasmsNCT06308406 · 54 planned · China
  3. Nov 12, 2024Phase 2 study in Prostatic NeoplasmsNCT06689163 · 66 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT05473624

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06689163Prostatic Neoplasms · China2RecruitingNov 30, 202566
NCT06308406Ovarian Neoplasms · China2RecruitingOct 202554
NCT05473624Advanced Solid Tumors · China1RecruitingDec 31, 2026153

How it is read

Names in the registry

  • “M9466”, 3 entries
  • “HRS-1167 tablets”, 1 entry
  • “HRS-1167”, 1 entry
  • “Bevacizumab; HRS-1167”, 1 entry

Codes read as this program: HRS1167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.